Epidemiology and management of hypertension in the hispanic population: A review of the available literature

American Journal of Cardiovascular Drugs

Volumn 12, Issue 3, 2012, Pages 165-178

  Guzman, Nicolas J ^a  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

antihypertensives; blood pressure monitoring; ethnic groups; hypertension

Indexed keywords

ALISKIREN; AMLODIPINE; ATENOLOL; CHLORTALIDONE; CLONIDINE; DILTIAZEM; DOXAZOSIN; ENALAPRIL; FELODIPINE; HYDROCHLOROTHIAZIDE; IRBESARTAN; ISRADIPINE; LISINOPRIL; LOSARTAN; NEBIVOLOL; OLMESARTAN; RAMIPRIL; TERAZOSIN; VALSARTAN; VERAPAMIL;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE; CARDIOVASCULAR RISK; COMORBIDITY; COMPARATIVE STUDY; DIABETES MELLITUS; DRUG DOSE TITRATION; DRUG EFFICACY; ETHNIC DIFFERENCE; HISPANIC; HUMAN; HYPERTENSION; LIFESTYLE; METABOLIC SYNDROME X; OBESITY; OUTCOME ASSESSMENT; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; TRANSDERMAL PATCH; TREATMENT DURATION;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HISPANIC AMERICANS; HUMANS; HYPERTENSION; OUTCOME ASSESSMENT (HEALTH CARE); PRACTICE GUIDELINES AS TOPIC; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; UNITED STATES;

EID: 84861320673     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/11631520-000000000-00000     Document Type: Review

References (67)

1. Hispanics in the United States. US Census Bureau [online]. Available from URL: http://www.census.gov/population/www/socdemo/hispanic/files/Internet- Hispanic-in-US-2006.pdf [Accessed 2011 Aug 17]
2. Vivo RP, Krim SR, Cevik C, et al. Heart failure in Hispanics. J Am Coll Cardiol 2009; 53: 1167-75
3. Bahrami H, Kronmal R, Bluemke DA, et al. Differences in the incidence of congestive heart failure by ethnicity: the multi-ethnic study of atherosclerosis. Arch Intern Med 2008; 168: 2138-45
4. Roger VL, Go As, Lloyd-Jones DM, et al. Heart disease and stroke statistics- 2012 update: a report from the American Heart Association. Circulation 2012; 125: e2-20
5. Carroll W. Hypertension in America: estimates for the US civilian noninstitutionalized population, age 18 and older, 2008. Agency for Healthcare Research andQuality, Rockville,MD[online].Available fromURL: http://www.meps.ahrq.gov/mepsweb/data-files/publications/st315/stat315.shtml [Accessed 2011 Aug 17]
6. Carson AP, Howard G, Burke GL, et al. Ethnic differences in hypertension incidence among middle-aged and older adults: the multi-ethnic study of atherosclerosis. Hypertension 2011; 57: 1101-7
7. RedmondN, Baer HJ, Hicks LS. Health behaviors and racial disparity in blood pressure control in the National Health and Nutrition Examination Survey. Hypertension 2011; 57: 383-9
8. Hypertension-related mortality among Hispanic subpopulations - United States, 1995-2002. MMWR Morb Mortal Wkly Rep 2006; 55: 177-80
9. Bersamin A, Stafford RS, Winkleby MA. Predictors of hypertension awareness, treatment, and control among Mexican American women and men. J Gen Intern Med 2009; 24 Suppl. 3: 521-7
10. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-52 (Pubitemid 37553153)
11. Flack JM, Sica DA, Bakris G, et al. Management of high blood pressure in Blacks: an update of the International Society on Hypertension in Blacks consensus statement. Hypertension 2010; 56: 780-800
12. Park IU, Taylor AL. Race and ethnicity in trials of antihypertensive therapy to prevent cardiovascular outcomes: a systematic review. Ann Fam Med 2007; 5: 444-52 (Pubitemid 47535976)
13. Differences in prevalence of obesity among black, white, and Hispanic adults - United States, 2006-2008. MMWR Morb Mortal Wkly Rep 2009; 58: 740-4
14. Wang Y, Beydoun MA, Liang L, et al. Will all Americans become overweight or obese? Estimating the progression and cost of the US obesity epidemic. Obesity (Silver Spring) 2008; 16: 2323-30
15. Sorlie PD, Backlund E, Johnson NJ, et al. Mortality by Hispanic status in the United States. JAMA 1993; 270: 2464-8 (Pubitemid 23342296)
16. Patel KV, Eschbach K, Ray LA, et al. Evaluation of mortality data for older Mexican Americans: implications for the Hispanic paradox. Am J Epidemiol 2004; 159: 707-15 (Pubitemid 38405385)
17. Keenan NL, Shaw KM. Coronary heart disease and stroke deaths - United States, 2006. MMWR Surveill Summ 2011; 60 Suppl.: 62-6
18. RosenbergHM, Maurer JD, Sorlie PD, et al. Quality of death rates by race and Hispanic origin: a summary of current research, 1999. Vital Health Stat 2 1999; 1-13
19. Smith DP, Bradshaw BS. Rethinking the Hispanic paradox: death rates and life expectancy for US non-Hispanic White and Hispanic populations. Am J Public Health 2006; 96: 1686-92 (Pubitemid 44300936)
20. Stern MP, Wei M. Do Mexican Americans really have low rates of cardiovascular disease? Prev Med 1999; 29 (6 Pt 2): S90-5 (Pubitemid 30032592)
21. Franzini L, Ribble JC, Keddie AM. Understanding the Hispanic paradox. Ethn Dis 2001; 11: 496-518 (Pubitemid 33584373)
22. Abra?́do-Lanza AF, Chao MT, Flórez KR. Do healthy behaviors decline with greater acculturation? Implications for the Latino mortality paradox. Soc Sci Med 2005; 61: 1243-55 (Pubitemid 40828568)
23. Gardin JM, Allebban Z, Wong ND, et al. Do differences in subclinical cardiovascular disease in Mexican Americans versus European Americans help explain the Hispanic paradox? Am J Cardiol 2010; 105: 205-9
24. Gallo LC, Penedo FJ, Espinosa de los Monteros K, et al. Resiliency in the face of disadvantage: do Hispanic cultural characteristics protect health outcomes? J Pers 2009; 77: 1707-46
25. Hunt KJ, Resendez RG, Williams K, et al. All-cause and cardiovascular mortality among Mexican-American and non-Hispanic White older partic- ipants in the San Antonio Heart Study: evidence against the ''Hispanic paradox''. Am J Epidemiol 2003; 158: 1048-57 (Pubitemid 37475088)
26. Hunt KJ, Williams K, Resendez RG, et al. All-cause and cardiovascular mortality among diabetic participants in the San Antonio Heart Study: evidence against the ''Hispanic Paradox''. Diabetes Care 2002; 25:1557-63 (Pubitemid 41071111)
27. Palmer Alves T, Lewis J. Racial differences in chronic kidney disease (CKD) and end-stage renal disease (ESRD) in the United States: a social and economic dilemma. Clin Nephrol 2010; 74 (Suppl. 1): S72-7
28. Morgenstern LB, Smith MA, Lisabeth LD, et al. Excess stroke in Mexican Americans compared with non-Hispanic whites: the Brain Attack Surveillance in Corpus Christi Project. Am J Epidemiol 2004; 160: 376-83 (Pubitemid 39045269)
29. Cooper-DeHoff RM, Aranda Jr JM, Gaxiola E, et al. Blood pressure control and cardiovascular outcomes in high-risk Hispanic patients: findings from the International Verapamil SR/Trandolapril Study (INVEST). Am Heart J 2006; 151: 1072-9
30. Margolis KL, Piller LB, Ford CE, et al. Blood pressure control in Hispanics in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension 2007; 50: 854-61 (Pubitemid 350287526)
31. Cooper-DeHoff RM, Zhou Q, Gaxiola E, et al. Influence of Hispanic ethnicity on blood pressure control and cardiovascular outcomes in women with CAD and hypertension: findings from INVEST. J Womens Health (Larchmt ) 2007; 16: 632-40 (Pubitemid 47093907)
32. Liao Y, Bang D, Cosgrove S, et al. Surveillance of health status in minority communities-Racial and Ethnic Approaches to Community Health Across the U.S. (REACH U.S.) Risk Factor Survey, United States, 2009. MMWR Surveill Summ 2011; 60: 1-44
33. Traylor AH, Schmittdiel JA, Uratsu CS, et al. Adherence to cardiovascular disease medications: does patient-provider race/ethnicity and language concordance matter? J Gen Intern Med 2010; 25: 1172-7
34. Eamranond PP, Wee CC, Legedza AT, et al. Acculturation and cardiovascular risk factor control among Hispanic adults in the United States. Public Health Rep 2009; 124: 818-24
35. Mensah GA, Dietz WH, Harris VB, et al. Prevention and control of coronary heart disease and stroke - nomenclature for prevention approaches in public health: a statement for public health practice from the Centers for Disease Control and Prevention. Am J Prev Med 2005; 29: 152-7 (Pubitemid 43021831)
36. Francis CK, Alpert JS, Clark LT, et al. Working group 3: How to encourage more minorities to choose a career in cardiology. J Am Coll Cardiol 2004; 44: 241-5 (Pubitemid 38950576)
37. Rustveld LO, Pavlik VN, Jibaja-Weiss ML, et al. Adherence to diabetes selfcare behaviors in English- and Spanish-speaking Hispanic men. Patient Prefer Adherence 2009; 3: 123-30
38. Stewart SH, Silverstein MD. Racial and ethnic disparity in blood pressure and cholesterol measurement. J Gen Intern Med 2002; 17: 405-11 (Pubitemid 34989005)
39. DeNavas-Walt C, Proctor BD, Smith JC. U.S. Census Bureau, Current Population Reports, P60-238, Income, Poverty, and Health Insurance Coverage in the United States: 2009, U.S. Government Printing Office, Washington, DC: 2010
40. Punzi H, Lewin A, Lukic T, et al. Efficacy and safety of nebivolol in Hispanics with stage I-II hypertension: a randomized placebo-controlled trial. Ther Adv Cardiovasc Dis 2010; 4: 349-57
41. Wright Jr JT, Lacourcière Y, Samuel R, et al. 24-Hour ambulatory blood pressure response to combination valsartan/hydrochlorothiazide and amlodipine/ hydrochlorothiazide in stage 2 hypertension by ethnicity: the EVALUATE study. J Clin Hypertens (Greenwich ) 2010; 12: 833-40
42. Ofili EO, Ferdinand KC, Saunders E, et al. Irbesartan/HCTZ fixed combinations in patients of different racial/ethnic groups with uncontrolled systolic blood pressure on monotherapy. J Natl Med Assoc 2006; 98: 618-26
43. Herrera CR, Lewin A, Fiddes R, et al. Long-acting diltiazem CD is safe and effective in a hypertensive Mexican-American population. Pharmacotherapy 1997; 17: 1254-9 (Pubitemid 27518037)
44. Prisant LM, WeberM, Black HR. Chronotherapeutic oral drug absorption system verapamil is effective in reducing morning blood pressure in African Americans: a post hoc analysis of the Chrono trial. J Natl Med Assoc 2005; 97: 377-83 (Pubitemid 40315942)
45. Black HR, ElliottWJ, WeberMA, et al. One-year study of felodipine or placebo for stage 1 isolated systolic hypertension. Hypertension 2001; 38: 1118-23 (Pubitemid 34252816)
46. Fuenmayor NT, Faggin BM, Cubeddu LX. Comparative efficacy, safety and pharmacokinetics of verapamil SR vs verapamil IR in hypertensive patients. Drugs 1992; 44 Suppl. 1: 1-11
47. Fuenmayor NT, Faggin BM, Cubeddu LX. Comparative efficacy, safety, and kinetics of immediate- and slow-release verapamil in Hispanic patients with essential hypertension. J Cardiovasc Pharmacol 1989; 13 Suppl. 4: S53-6 (Pubitemid 19190256)
48. Dias VC, Tendler B, Oparil S, et al. Clinical experience with transdermal clonidine in African-American and Hispanic-American patients with hypertension: evaluation from a 12-week prospective, open-label clinical trial in community-based clinics. Am J Ther 1999; 6: 19-24 (Pubitemid 29048589)
49. Harris SI, Alvarez C. a2-agonist versus a1-antagonist in mild-to-moderate hypertension: comparison of transdermal clonidine and terazosin monotherapies. Am J Ther 1997; 4: 9-15 (Pubitemid 27183972)
50. Weir MR, Chrysant SG, McCarron DA, et al. Influence of race and dietary salt on the antihypertensive efficacy of an angiotensin-converting enzyme inhibitor or a calcium channel antagonist in salt-sensitive hypertensives. Hypertension 1998; 31: 1088-96 (Pubitemid 28191502)
51. Everett BM, Glynn RJ, Danielson E, et al. Combination therapy versus monotherapy as initial treatment for stage 2 hypertension: a prespecified subgroup analysis of a community-based, randomized, open-label trial. Clin Ther 2008; 30: 661-72 (Pubitemid 351680499)
52. Phillips RA, Kloner RA, Grimm Jr RH, et al. The effects of amlodipine compared to losartan in patients with mild to moderately severe hypertension. J Clin Hypertens (Greenwich ) 2003; 5: 17-23
53. Ofili EO, Oparil S, Giles T, et al. Moderate versus intensive treatment of hypertension using amlodipine/valsartan and with the addition of hydrochlorothiazide for patients uncontrolled on angiotensin receptor blocker monotherapy: results in racial/ethnic subgroups. J Am Soc Hypertens 2011; 5: 249-58
54. Ofili EO, Cable G, Neutel JM, et al. Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in hypertensive women: the INCLUSIVE trial. J Womens Health (Larchmt ) 2008; 17: 931-8
55. Whaley-Connell A, Purkayastha D, Ricks Z, et al. Ethnic differences in response to combination aliskiren/HCTZ vs ramipril monotherapy in obese patients with stage 2 hypertension [abstract PO-67]. JClinHypertens 2010; 12 Suppl. 1:A46-7
56. Littlejohn T, Oparil S, Melino M, et al. Efficacy and safety of combination olmesartan medoxomil (OM)+amlodipine besylate (AML) +hydrochlorothiazide (HCTZ): a subgroup analysis by ethnicity and BMI [abstract 2134-PO]. Diabetes 2010; 59 Suppl. 1: 2134
57. Black HR, Palacios FA, Arango JL, et al. Aliskiren alone or in combination with hydrochlorothiazide lowers BP effectively in Hispanic/Latino patients with systolic BP 160-<180mm hg (aquire study) [abstract po-16] J Clin Hypertens 2010 12 SUPPL. 1 A24
58. Ferdinand K, Weitzman R, Purkayastha D, et al. Combination direct renin inhibitor/ calciumchannel blockerwith orwithout diuretic effectively lowers blood pressure (BP) in Hispanic patients with stage 2 hypertension: a subgroup analysis of the aliksiren+amlodipine-HCTZ in minority patients with stage 2 hypertension (ASCENT) study [abstract P174]. Hypertension 2011; 58: e78-9
59. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28: 1462-536
60. Hsueh WA, Wyne K. Renin-Angiotensin-aldosterone system in diabetes and hypertension. J Clin Hypertens (Greenwich ) 2011; 13: 224-37
61. Hershon KS. Mechanistic and clinical aspects of renin-angiotensin- aldosterone system blockade in the prevention of diabetes mellitus and cardiovascular disease. Endocr Pract 2011; 17: 430-40
62. D'Elia JA, Bayliss G, Roshan B, et al. Diabetic microvascular complications: possible targets for improved macrovascular outcomes. Int J Nephrol Renovasc Dis 2011; 4: 1-15
63. Whaley-Connell A, Purkayastha D, Yadao A, et al. Central pressure and biomarker responses to renin inhibition with hydrochlorothiazide and ramipril in obese hypertensive: the ATTAIN study. Cardiorenal Med 2011; 1: 53-66
64. Oparil S, Melino M, Lee J, et al. Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: the TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. Clin Ther 2010; 32 (7): 1252-69
65. Uresin Y, Taylor AA, Kilo C, et al. Efficacy and safety of the direct rennin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst 2007; 8: 190-8 (Pubitemid 351166266)
66. Black HR, Kribben A, Aguirre PF, et al. Aliskiren alone or in combination with hydrochlorothiazide in patients with the lower ranges of stage 2 hypertension: the ACQUIRE randomized double-blind study. J Clin Hypertens (Greenwich ) 2010; 12: 917-26
67. Ferdinand KC, Weitzman R, Israel M, et al. Efficacy and safety of aliskirenbased dual and triple combination therapies in US minority patients with stage 2 hypertension. J Am Soc Hypertens 2011; 5: 102-13